viewMatinas BioPharma

Matinas BioPharma commences enrollment and starts dosing in study of MAT9001 to treat cardiovascular and metabolic conditions

The company also said it will soon resume dosing patients in the EnACT study of MAT2203 to treat serious invasive fungal infections

Matinas BioPharma - Matinas BioPharma Holdings Inc commences enrollment and dosing in the ENHANCE-IT study of MAT9001 for the treatment of cardiovascular and metabolic conditions
Both studies had temporarily paused enrollment in March due to the COVID-19 pandemic

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) announced Tuesday that it has commenced enrollment and started dosing patients in the ENHANCE-IT study of MAT9001 for the treatment of cardiovascular and metabolic conditions.

The company also said it expects to resume dosing patients in the EnACT study imminently, following the recent receipt of necessary governmental and regulatory approvals in Uganda. That study involves MAT2203, an oral formulation of amphotericin B to treat serious invasive fungal infections.

Both studies had temporarily paused enrollment in March due to the COVID-19 pandemic. 

READ: Matinas BioPharma appoints James Underberg to its MAT9001 scientific advisory board

“I am extremely pleased with our execution and progress during a period of significant uncertainty, given all of the ramifications of the ongoing COVID-19 pandemic. Resuming enrollment in both ENHANCE-IT and EnACT were critical milestones for our company and position us to deliver potentially clinically meaningful Phase 2 data for our lead products relatively quickly,” said CEO Jerome Jabbour in a statement. 

“We believe we have taken the appropriate steps to ensure the safety of clinical trial participants and caregivers and we remain grateful for their commitment to our important clinical work. We look forward to completing these studies within our previously communicated timelines and believe each study represents a significant value-creating opportunity.”

In early June, the company said it resumed enrollment and began dosing patients in the ENHANCE-IT trial, a head-to-head study of MAT9001 versus the industry standard Vascepa. It expects to complete enrollment in August, with topline data available in the first quarter of 2021.

In late June, Matinas said it received approval from the Uganda National Drug Authority to restart the EnACT study. The first cohort of patients is expected to fully enroll by early September based upon projections from Dr David Boulware, the principal investigator for the trial.

Evaluation of data from the first cohort of patients by the independent Data and Safety Monitoring Board and anticipated progression from the first patient cohort to the second patient cohort is expected during the fourth quarter of 2020, the Bedminster, New Jersey-based biopharmaceutical company said. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Matinas BioPharma

Price: 0.7004 USD

Market: NYSE
Market Cap: $139.29 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Matinas BioPharma named herein, including the promotion by the Company of Matinas BioPharma in any Content on the Site, the Company receives...



Full interview: Matinas BioPharma to begin dosing HIV patients with...

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) CEO Jerome Jabbour tells Proactive it will begin a Part 2 study of MAT2203 for the treatment of HIV patients with cryptococcal meningitis. Jabbour explains how the New Jersey-based company will begin dosing its first patient in the...

on 02/24/2020

2 min read